Antineoplaston clinic should be considered a manufacturer subject to federal statute -- Kessler to Rep. Barton.
ANTINEOPLASTON CLINIC SHOULD BE CONSIDERED A DRUG MANUFACTURER subject to federal statute covering drug manufacturers, FDA Commissioner Kessler suggested at a second hearing on alleged FDA retaliation held by Rep. Barton's (R-Tex.) Commerce/Oversight Subcommittee Dec. 5. "There is a very big difference, in my opinion, between dealing with someone who manufactures a drug, what we call at FDA a sponsor," and someone who dispenses a drug to an individual patient faced with a life-threatening illness, Kessler said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth